Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCyte InternationalTPE:4178 -2.39%7 PB Ratio is 2.09 as of Aug. 09, 2026, which is 26% below its 10-year median of 2.84. GuruFocus rates TPE:4178 with a GF Score™ of 7/100. The stock has 4 warning signs investors should review. Among 1,225 Biotechnology companies, StemCyte International ranks better than 61.96% on this metric.
StemCyte International Ltd stock PB Ratio (=2.09) is close to 2-year low of 1.97.
The historical rank and industry rank for StemCyte International's PB Ratio or its related term are showing as below:
TPE:4178'
s PB Ratio Range Over the Past 10 Years
Min: 1.97 Med: 2.84 Max: 3.83
Current: 2.09
During the past 4 years, StemCyte International's highest PB Ratio was 3.83. The lowest was 1.97. And the median was 2.84.
TPE:4178's PB Ratio is ranked better than 61.96% of 1225
companies
in the Biotechnology industry
Industry Median: 2.94
vs TPE:4178: 2.09
During the past 3 years, the average Book Value Per Share Growth Rate was 69.70% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of StemCyte International was 69.70% per year. The lowest was 69.70% per year. And the median was 69.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, StemCyte International's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCyte International PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCyte International's PB Ratio distribution charts can be found below:
* The bar in red indicates where StemCyte International's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
StemCyte International (TPE:4178) has a PB Ratio of 2.09 as of Aug. 09, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on StemCyte International and its competitors. This is 26% below median its historical median of 2.84. Over the past decade, StemCyte International's PB Ratio has ranged from 1.97 to 3.83. According to the industry distribution chart, StemCyte International ranks #466 out of 1225 companies in the Biotechnology industry, placing it in the top 38%.
Is StemCyte International's PB Ratio too high?
StemCyte International's current PB Ratio of 2.09 is 26% below median its 10-year median of 2.84. Over the past 10 years, this metric has ranged from a low of 1.97 to a high of 3.83. The Biotechnology industry median PB Ratio is 2.94. StemCyte International's value of 2.09 is 28.9% below this industry median. Based on the distribution chart, StemCyte International ranks #466 out of 1225 companies in the Biotechnology industry, which is above the industry midpoint. Overall, StemCyte International has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does StemCyte International's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCyte International ranks #466 out of 1225 companies for PB Ratio. This puts StemCyte International in the upper half of its industry. The industry median PB Ratio is 2.94. StemCyte International's value of 2.09 is 28.9% below this benchmark. Historically, StemCyte International's own PB Ratio has ranged from 1.97 to 3.83 over the past decade. While the company's 10-year median is 2.84 vs. the industry median of 2.94, StemCyte International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.94, based on 1,225 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. StemCyte International's current PB Ratio of 2.09 is 28.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on StemCyte International and its competitors. For the Biotechnology industry, the median PB Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCyte International's current PB Ratio is 2.09, which is 26% below median its own 10-year median of 2.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCyte International stock overvalued right now?
StemCyte International (TPE:4178) has a current PB Ratio of 2.09. The current PB Ratio is 2.09, which is 26% below median its 10-year median of 2.84 and 28.9% below the Biotechnology industry median of 2.94. StemCyte International's overall GF Score™ is 7/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For StemCyte International (TPE:4178), the current PB Ratio is 2.09 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
StemCyte International Ltd is engaged in developing new stem cell drugs and test, process, and store umbilical cord blood (UCB)-related cells. The company's main operating activities are providing umbilical cord blood collection, processing and storage services. Its reportable segments are the United States, Taiwan, and Others. The majority of revenue is derived from the United States.
7GF Score
Get the complete analysis for TPE:4178
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4178 has been successfully added to your 
